Chrysalis

Chrysalis (Eureka, MT) is a SAMHSA Behavioral Health Treatment Services Locator-registered facility. The facility offers specific levels of care: Inpatient, Dual Dx. Evaluation of this facility against current clinical standards should encompass ASAM 4e framework alignment, MAT policy, and payer-specific network status.

Care levels at Chrysalis

Level-of-care documentation: The facility's documented care levels are The facility offers specific levels of care: Inpatient, Dual Dx. — each of which is appropriate for specific clinical presentations. Matching the level to the specific clinical need is the pre-admission work. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Chrysalis operates primarily on commercial insurance. The implication for patients: higher typical cost-share, potentially more intensive programming, and the full burden of MHPAEA parity-rule dynamics — including appeal rights when the plan denies. The operational prerequisite for admission is written documentation of: (a) network contract status; (b) prior authorization; (c) cost-sharing structure; (d) medical-necessity criteria applied. Absence of any of these four increases the probability of post-admission financial disagreement.

Specialty programming

The facility's documented specialty programming includes: Members of military families, Clients with co-occurring mental and substance use disorders, Clients who have experienced trauma. Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Pre-admission documentation for Chrysalis should include ASAM-framework level-of-care justification, plan-specific Verification of Benefits with network-contract confirmation, written MAT policy for opioid use disorder patients where applicable, and licensure/accreditation verification. If the clinical situation involves opioid use disorder, confirm explicitly whether Chrysalis offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.